TWI890704B - 用於失智症之glp-1受體促效劑 - Google Patents

用於失智症之glp-1受體促效劑

Info

Publication number
TWI890704B
TWI890704B TW109138851A TW109138851A TWI890704B TW I890704 B TWI890704 B TW I890704B TW 109138851 A TW109138851 A TW 109138851A TW 109138851 A TW109138851 A TW 109138851A TW I890704 B TWI890704 B TW I890704B
Authority
TW
Taiwan
Prior art keywords
glp
dementia
receptor agonist
administered
disease
Prior art date
Application number
TW109138851A
Other languages
English (en)
Chinese (zh)
Other versions
TW202118509A (zh
Inventor
莎拉 弗里德里西
夏洛特 克利斯汀 蒂姆 漢森
洛特 比耶爾 庫努森
安娜 賽徹爾
Original Assignee
丹麥商諾佛 儂迪克股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73172681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI890704(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 丹麥商諾佛 儂迪克股份有限公司 filed Critical 丹麥商諾佛 儂迪克股份有限公司
Publication of TW202118509A publication Critical patent/TW202118509A/zh
Application granted granted Critical
Publication of TWI890704B publication Critical patent/TWI890704B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW109138851A 2019-11-06 2020-11-06 用於失智症之glp-1受體促效劑 TWI890704B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19207501.8 2019-11-06
EP19207501 2019-11-06
EP20186623 2020-07-20
EP20186623.3 2020-07-20

Publications (2)

Publication Number Publication Date
TW202118509A TW202118509A (zh) 2021-05-16
TWI890704B true TWI890704B (zh) 2025-07-21

Family

ID=73172681

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109138851A TWI890704B (zh) 2019-11-06 2020-11-06 用於失智症之glp-1受體促效劑
TW114103408A TWI923289B (zh) 2019-11-06 2020-11-06 用於失智症之glp-1受體促效劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW114103408A TWI923289B (zh) 2019-11-06 2020-11-06 用於失智症之glp-1受體促效劑

Country Status (19)

Country Link
US (4) US20220280612A1 (cg-RX-API-DMAC7.html)
EP (2) EP4054620B1 (cg-RX-API-DMAC7.html)
JP (2) JP7670698B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220110731A (cg-RX-API-DMAC7.html)
CN (1) CN114728042A (cg-RX-API-DMAC7.html)
AU (1) AU2020377469A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007721A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154744A1 (cg-RX-API-DMAC7.html)
ES (1) ES2984177T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241052T1 (cg-RX-API-DMAC7.html)
HU (1) HUE067514T2 (cg-RX-API-DMAC7.html)
IL (1) IL291876A (cg-RX-API-DMAC7.html)
MA (1) MA57599B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022004779A (cg-RX-API-DMAC7.html)
PH (1) PH12022550842A1 (cg-RX-API-DMAC7.html)
PL (1) PL4054620T3 (cg-RX-API-DMAC7.html)
RS (1) RS65780B1 (cg-RX-API-DMAC7.html)
TW (2) TWI890704B (cg-RX-API-DMAC7.html)
WO (1) WO2021089678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3154744A1 (en) 2019-11-06 2021-05-14 Sarah FRIEDRICH Glp-1 receptor agonists in dementia
US20230088005A1 (en) * 2020-01-30 2023-03-23 Eli Lilly And Company Therapeutic uses of dulaglutide
EP4262873A4 (en) * 2020-12-16 2024-12-11 The Chinese University of Hong Kong A method for reversing aging brain functional decline
CN118510545A (zh) 2021-12-02 2024-08-16 哥本哈根大学 用于治疗神经退行性疾病的肽-药物缀合物
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
WO2026096637A1 (en) * 2024-10-30 2026-05-07 Tiziana Life Sciences Plc Glp-1 agonists and foralumab combination therapies
CN120131965A (zh) * 2025-04-10 2025-06-13 瓯江实验室 Glp-1受体激动剂治疗阿尔茨海默病的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016198624A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
EP1411968B1 (en) 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
MX2008001468A (es) 2005-06-30 2008-04-07 Sod Conseils Rech Applic Composiciones farmaceuticas del peptido similar al glucagon-1.
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2066337A2 (en) 2006-08-04 2009-06-10 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
MX2009002121A (es) 2006-09-07 2009-05-20 Hoffmann La Roche Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico.
US8756102B2 (en) * 2009-11-06 2014-06-17 Edatanetworks Inc. Method, system, and computer program for attracting local and regional businesses to an automated cause marketing environment
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
HUE049152T2 (hu) * 2012-07-01 2020-09-28 Novo Nordisk As Hosszantartó hatású GLP-1 peptidek alkalmazása
WO2015155151A1 (en) 2014-04-07 2015-10-15 Novo Nordisk A/S Double-acylated glp-1 compounds
AU2016379403B2 (en) * 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
US20190142905A1 (en) 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
CA3154744A1 (en) 2019-11-06 2021-05-14 Sarah FRIEDRICH Glp-1 receptor agonists in dementia
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016198624A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Liping Zhang Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model Neuropeptides 71 July 2018 1-11 *

Also Published As

Publication number Publication date
RS65780B1 (sr) 2024-08-30
WO2021089678A1 (en) 2021-05-14
EP4054620A1 (en) 2022-09-14
EP4414031A3 (en) 2025-02-05
TW202519256A (zh) 2025-05-16
ES2984177T3 (es) 2024-10-29
MA57599B1 (fr) 2024-06-28
MX2022004779A (es) 2022-06-14
TWI923289B (zh) 2026-04-21
JP2023500032A (ja) 2023-01-04
IL291876A (en) 2022-06-01
EP4054620C0 (en) 2024-05-29
BR112022007721A2 (pt) 2022-07-12
KR20220110731A (ko) 2022-08-09
PL4054620T3 (pl) 2024-10-14
CA3154744A1 (en) 2021-05-14
EP4414031A2 (en) 2024-08-14
TW202118509A (zh) 2021-05-16
US20220280612A1 (en) 2022-09-08
EP4054620B1 (en) 2024-05-29
US12539326B2 (en) 2026-02-03
US20240207364A1 (en) 2024-06-27
HRP20241052T1 (hr) 2024-11-08
US20250099549A1 (en) 2025-03-27
JP7670698B2 (ja) 2025-04-30
PH12022550842A1 (en) 2023-10-09
CN114728042A (zh) 2022-07-08
US20230302094A1 (en) 2023-09-28
AU2020377469A1 (en) 2022-04-28
HUE067514T2 (hu) 2024-10-28
JP2025027130A (ja) 2025-02-26

Similar Documents

Publication Publication Date Title
US12539326B2 (en) Methods for treating Alzheimer's disease using semaglutide
US20250082651A1 (en) Ganaxolone for use in treating genetic epileptic disorders
JP6561136B2 (ja) 勃起機能不全を治療又は改善するための方法及びsglt2阻害薬を含む医薬組成物
US20200338040A1 (en) Methods for treating alzheimer's disease and related disorders
US10463655B2 (en) Method of treatment with tradipitant
US20250152672A1 (en) Semaglutide for use in medicine
US20230098944A1 (en) Method of decreasing amyloid beta monomer levels in patients with cognitive decline
BR112019023557A2 (pt) Composição farmacêutica compreendendo inibidor de pde9
AU763273B2 (en) Analgesic regimen
EA052078B1 (ru) Агонисты рецептора glp-1 при лечении деменции
EA046973B1 (ru) Агонисты рецептора glp-1 при лечении деменции
HK40075453A (en) Semaglutide in the treatment of alzheimer's dementia
US20200038414A1 (en) Methods of treating constipation using aminosterol compositions
US11213494B2 (en) Compositions and methods for the treatment of pervasive development disorders
EP4695225A1 (en) Treatment for amyotrophic lateral sclerosis (als)
HK1155659B (en) Pharmaceutical composition for treatment of fibromyalgia
HK1155659A1 (en) Pharmaceutical composition for treatment of fibromyalgia